United Kingdom Semen Analysis Market Forecast 2025-2032

The United Kingdom semen analysis market is predicted to grow with a CAGR of 6.08% over the forecast period 2025-2032. The market was valued at $69.04 million in 2024 and is expected to reach a revenue of $111.03 million by 2032.

The growth of the semen analysis market in the United Kingdom is attributed to increasing incidences of infertility, advancements in diagnostic technologies, the expansion of fertility clinics and ART centers, and growing awareness of reproductive health.

MARKET INSIGHTS

The rising preference for at-home semen test kits also contributes to market expansion by offering convenience and privacy. However, the UK market faces challenges such as the high costs of advanced diagnostic procedures sociocultural stigmas associated with male infertility and fertility testing.

According to the Office for National Statistics (ONS), live births in the UK declined to 591,072 in 2023, a decrease from 605,479 in 2022 and over 640,000 in 2021. This decline highlights a consistent downward trend since 2012. Furthermore, the total fertility rate (TFR) reached a historic low of 1.44 children per woman in 2023, down from 1.49 in 2022.

This marks the lowest level since records began in 1938, reflecting a demographic shift that highlights the growing importance of reproductive health solutions and fertility diagnostics in the UK. The use of semen analysis tests continues to rise as a result of these challenges.

Technological advancements are playing a pivotal role in shaping the UK semen analysis testing market. Companies like Mojo Fertility have introduced AI-powered solutions to meet the rising demand for convenient and private diagnostics.

Launched in 2022, Mojo’s at-home semen test kits utilize artificial intelligence to assess critical sperm parameters such as count, motility, and morphology. These innovations are enabling individuals to take control of their reproductive health while ensuring accurate and reliable results, including a semen motility check and semen quality assessment.

Microscopic examination remains a widely used method for laboratory testing of semen in clinical settings due to its cost-effectiveness and ability to deliver reliable results. This traditional approach allows healthcare professionals to directly observe and analyze sperm characteristics, providing foundational insights into male fertility.

However, advanced technologies, including automated semen analyzers, are gaining prominence for their ability to overcome limitations in traditional techniques. These innovations offer enhanced accuracy, consistency, and scalability, making them invaluable in both clinical and home-based settings.

As the demand for precise diagnostics grows, future demand in the semen analysis market is expected to be driven by innovations such as AI-powered tools and manual semen analyzers, improving both the male fertility test experience and the sperm health check process.

SEGMENTATION ANALYSIS

The United Kingdom semen analysis market is segmented into diagnostic technique, testing kits and reagents, age group, and end-user. The end-user category is further classified into hospitals, fertility centers, diagnostic laboratories, and other end-users.

Under the end-user segment, hospitals play a critical role in providing semen analysis services. In hospital settings, semen analysis is typically conducted as part of a comprehensive fertility evaluation or to diagnose underlying conditions affecting male reproductive health.

These facilities are equipped with advanced diagnostic technologies, such as CASA systems and traditional microscopy, ensuring accurate assessments of sperm count, motility, morphology, and other parameters. Hospitals also act as referral centers, collaborating with fertility clinics and ART centers to support patients requiring specialized treatments.

With declining fertility rates and the growing demand for accessible diagnostic solutions, the UK semen analysis market is poised for substantial growth. While addressing cost and accessibility barriers remains critical, the integration of AI technologies and the adoption of innovative diagnostic tools position the UK as a significant player in advancing reproductive health care.

COMPETITIVE INSIGHTS

Some of the leading players in the United Kingdom semen analysis market include bioMérieux SA, Cooper Companies Inc, Mojo, Hamilton Thorne Inc, etc.

Mojo is a UK-based fertility startup specializing in AI-powered, at-home sperm analysis. Their services enable men to assess key sperm health parameters—such as count, motility, and morphology—from the comfort of their homes, eliminating the need for clinic visits.

Founded in 2017 by Mohamed Taha, Daniel Thomas, Fanny Chesa, and Tobias Boecker, Mojo developed a proprietary AI-driven microscope, the Mojo AISA, which offers 97% accuracy in sperm analysis. This technology has been validated by leading institutions, including King’s College London and the Karolinska Institute, ensuring compliance with World Health Organization standards.